Leaders in Immunotherapy

ABOUT US

HELPING TO BEAT CANCER, ONE VACCINE AT A TIME.

ImmunoRestoration, Inc. was formed in 2016 to commercialize groundbreaking immunotherapeutic cancer vaccine research begun in 2004 at the University of Pennsylvania. The decision to pursue this opportunity was made after carefully evaluating data associated with pre-clinical research and studies involving more than 100 patients. Late in 2017, the company acquired the global exclusive rights to bring this technology to market and is now poised to help usher in a new era of precision, patient-centric cancer treatment. 

Our Science

ImmunoRestoration’s core technology (Immune Conditioning via Activated Innate (autologous) Transfer - ICAIT™ ) is a novel, integrated dendritic cell-based immunization system to overcome some of the known obstacles facing anti-cancer vaccines:  Breakthrough finding: HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact both invasive breast cancer as well as ductal carcinoma in situ."

News & Events